UnknownNCT03674255

Use of Imaging and Blood Biomarkers to Improve the Diagnostic Accuracy of Cardiac Assessment by Stress Echocardiogram

Sponsor: University of Oxford

Trial Details

Condition	Coronary Artery Disease, Ischaemic Heart Disease, Angina Pectoris
Status	Unknown
Participants	23,000
Est. Completion	1 Mar 2021
Last Updated	29 Apr 2026

Primary Outcome

Assessment of Prognostically Significant CAD; Examination of Medical Records

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Patients must be undergoing a stress echocardiogram to investigate the presence of ischaemic heart disease (groups 1-3). * Patients must be able to provide informed consent. * Patients must be aged over 18 years of age. Exclusion Criteria: * Patients undergoing stress echocardiography to assess valvular function. * Patients who are unwilling or unable to provide informed consent. * Patients aged under 18 years of age.

View Registry Entry

Related Analysis

EVAREST Study: Novel Blood and Imaging Biomarkers to Enhance Stress Echocardiography Accuracy in Coronary Disease — What Clinicians Need to Know

The EVAREST study is investigating novel blood and imaging biomarkers to improve stress echocardiography accuracy in diagnosing coronary artery disease. This large UK-based observational study of 23,000 participants aims to reduce interpretation variability and enhance diagnostic confidence in cardiac assessment.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service